Company Information: Chugai Pharmaceutical Co. Ltd.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"Ticker":"4519","DATE":"2025-12-19","longName":"Chugai Pharmaceutical Co., Ltd.","company_name_ja":"\u4e2d\u5916\u88fd\u85ac(\u682a)","fullTimeEmployees":5104,"address":"","phone":"","website":"https:\/\/www.chugai-pharm.co.jp","industry":"Drug Manufacturers - General","sector":"Healthcare","regularMarketPrice":8291,"financialCurrency":"","marketCap":13644525,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":263.72000000000003,"epsForward":0,"bookValue":0,"totalRevenue":1257941000000,"OperatingIncome":598833000000,"operatingMargins":47.600000000000001,"NetIncome":434012000000,"profitMargins":34.5,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":21.420000000000002,"recommendationMean":1.8666700000000001,"recommendationKey":"buy","targetMeanPrice":9686.6669999999995,"numberOfAnalystOpinions":15,"analyst_earnings_data":"{\"success\": true, \"fetched_at\": \"2026-08-01T05:02:17.177565\", \"ticker\": \"4519\", \"ticker_full\": \"4519.T\", \"company_name\": \"CHUGAI PHARMACEUTICAL CO\", \"analyst_recommendations\": {\"has_data\": true, \"period\": \"3\", \"strong_buy\": 4, \"buy\": 5, \"hold\": 6, \"sell\": 0, \"strong_sell\": 0, \"total_analysts\": 15, \"recommendation_key\": \"buy\", \"recommendation_mean\": 1.86667}, \"target_prices\": {\"has_data\": true, \"current\": 6932.0, \"high\": 13300.0, \"low\": 8000.0, \"mean\": 9686.667, \"median\": 9700.0}, \"earnings_dates\": {\"has_data\": true, \"next_earnings\": {\"date\": \"2026-10-27\", \"eps_estimate\": 78.92, \"eps_actual\": null, \"surprise_pct\": null}, \"future_count\": 1, \"past_earnings\": [{\"date\": \"2026-07-24\", \"eps_estimate\": 74.57, \"eps_actual\": 70.69, \"surprise_pct\": -5.21}, {\"date\": \"2026-04-24\", \"eps_estimate\": 68.59, \"eps_actual\": 70.13, \"surprise_pct\": 2.25}, {\"date\": \"2026-01-28\", \"eps_estimate\": 72.09, \"eps_actual\": 78.02, \"surprise_pct\": 8.23}, {\"date\": \"2025-10-24\", \"eps_estimate\": 73.28, \"eps_actual\": 67.58, \"surprise_pct\": -7.77}, {\"date\": \"2025-07-24\", \"eps_estimate\": 75.76, \"eps_actual\": 59.04, \"surprise_pct\": -22.07}]}, \"shareholders\": {\"has_data\": true, \"insider_pct\": 59.89, \"institution_pct\": 19.85, \"major_holders\": [{\"label\": \"\", \"value\": 59.89}, {\"label\": \"\", \"value\": 19.85}, {\"label\": \"\", \"value\": 49.49}, {\"label\": \"\", \"value\": 419.0}], \"institutional_holders\": [{\"holder\": \"Pacer Advisors, Inc.\", \"shares\": 5943, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.0, \"pct_change\": 12.9, \"value\": 41196876}], \"mutualfund_holders\": [{\"holder\": \"VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund\", \"shares\": 9371350, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.56, \"pct_change\": 0.1, \"value\": 64962198200}, {\"holder\": \"VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund\", \"shares\": 8606142, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.51, \"pct_change\": 8.76, \"value\": 59657776344}, {\"holder\": \"VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund\", \"shares\": 6194752, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.37, \"pct_change\": 2.46, \"value\": 42942020864}, {\"holder\": \"HARDING LOEVNER Fd.S INC-Harding Loevner Intl Eqy. PORT.\", \"shares\": 4865200, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.29, \"pct_change\": -3.79, \"value\": 33725566400}, {\"holder\": \"iShares Trust-iShares Core MSCI EAFE ETF\", \"shares\": 4952500, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.29, \"pct_change\": 1.39, \"value\": 34330730000}, {\"holder\": \"NEW PERSPECTIVE FUND\", \"shares\": 4227000, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.25, \"pct_change\": 0.0, \"value\": 29301564000}, {\"holder\": \"T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Overseas Stock Fd.\", \"shares\": 3930800, \"date_reported\": \"2026-04-30\", \"pct_held\": 0.23, \"pct_change\": 4.71, \"value\": 27248305600}, {\"holder\": \"-Price (T.Rowe) International Core Equity Trust\", \"shares\": 2818500, \"date_reported\": \"2026-03-31\", \"pct_held\": 0.17, \"pct_change\": -0.69, \"value\": 19537842000}, {\"holder\": \"iShares, Inc.-iShares MSCI Japan ETF\", \"shares\": 2905800, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.17, \"pct_change\": 6.22, \"value\": 20143005600}, {\"holder\": \"Fidelity Concord Street Trust-Fidelity International Index Fund\", \"shares\": 2585815, \"date_reported\": \"2026-06-30\", \"pct_held\": 0.15, \"pct_change\": 2.33, \"value\": 17924869580}]}}","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa\/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF\/anti Ang-2 bispecific antibody. The company has a collaboration with Chugai Pharmaceutical Co., Ltd. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":66,"get_dividend_history_year2":272,"get_dividend_history_year3":98,"get_dividend_history_year4":80,"get_dividend_history_year5":78,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"financial_data":"","detailed_financial_data":"{\"success\": true, \"fetched_at\": \"2026-08-09T03:25:40.445116\", \"ticker\": \"4519\", \"ticker_full\": \"4519.T\", \"company_name\": \"CHUGAI PHARMACEUTICAL CO\", \"company_info\": {\"name_en\": \"CHUGAI PHARMACEUTICAL CO\", \"long_name\": \"Chugai Pharmaceutical Co., Ltd.\", \"sector\": \"Healthcare\", \"industry\": \"Drug Manufacturers - General\", \"website\": \"https:\/\/www.chugai-pharm.co.jp\", \"employees\": 5104, \"country\": \"Japan\", \"city\": \"Chuo\", \"address\": \"Nihonbashi Mitsui Tower\", \"description\": \"Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Lunsumio, Perjeta, Phesgo, Polivy, and Tecentriq; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept, an immunosuppressant; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi, a spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa\/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF\/anti Ang-2 bispecific antibody. The company has a collaboration with Chugai Pharmaceutical Co., Ltd. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding AG.\"}, \"price_trend\": {\"ma_5\": {\"ma_value\": 6735.2, \"deviation\": 1.81, \"trend\": \"up\"}, \"ma_25\": {\"ma_value\": 7159.48, \"deviation\": -4.22, \"trend\": \"down\"}, \"ma_75\": {\"ma_value\": 7547.99, \"deviation\": -9.15, \"trend\": \"down\"}, \"ma_200\": {\"ma_value\": 8036.1, \"deviation\": -14.67, \"trend\": \"down\"}}, \"financials\": {\"years\": [{\"year\": 2025, \"revenue\": 1257941000000.0, \"revenue_fmt\": \"\u00a51.3T\", \"gross_profit\": 894251000000.0, \"gross_profit_fmt\": \"\u00a58943\u5104\", \"operating_income\": 598833000000.0, \"operating_income_fmt\": \"\u00a55988\u5104\", \"ebit\": 598014000000.0, \"ebit_fmt\": \"\u00a55980\u5104\", \"net_income\": 434012000000.0, \"net_income_fmt\": \"\u00a54340\u5104\", \"eps\": 263.72, \"operating_margin\": 47.6, \"total_assets\": 2468595000000.0, \"total_assets_fmt\": \"\u00a52.5T\", \"total_equity\": 2025732000000.0, \"total_equity_fmt\": \"\u00a52.0T\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 426602000000.0, \"total_cash_fmt\": \"\u00a54266\u5104\", \"equity_ratio\": 82.06, \"de_ratio\": 0.0, \"current_ratio\": 4.23, \"operating_cf\": 386280000000.0, \"operating_cf_fmt\": \"\u00a53863\u5104\", \"investing_cf\": -201273000000.0, \"investing_cf_fmt\": \"-\u00a52013\u5104\", \"financing_cf\": -307886000000.0, \"financing_cf_fmt\": \"-\u00a53079\u5104\", \"free_cf\": 274673000000.0, \"free_cf_fmt\": \"\u00a52747\u5104\", \"net_margin\": 34.5, \"roe\": 21.42, \"roa\": 17.58}, {\"year\": 2024, \"revenue\": 1170611000000.0, \"revenue_fmt\": \"\u00a51.2T\", \"gross_profit\": 831201000000.0, \"gross_profit_fmt\": \"\u00a58312\u5104\", \"operating_income\": 542002000000.0, \"operating_income_fmt\": \"\u00a55420\u5104\", \"ebit\": 542002000000.0, \"ebit_fmt\": \"\u00a55420\u5104\", \"net_income\": 387317000000.0, \"net_income_fmt\": \"\u00a53873\u5104\", \"eps\": 235.36, \"operating_margin\": 46.3, \"total_assets\": 2208373000000.0, \"total_assets_fmt\": \"\u00a52.2T\", \"total_equity\": 1901499000000.0, \"total_equity_fmt\": \"\u00a51.9T\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 540202000000.0, \"total_cash_fmt\": \"\u00a55402\u5104\", \"equity_ratio\": 86.1, \"de_ratio\": 0.0, \"current_ratio\": 5.53, \"operating_cf\": 447600000000.0, \"operating_cf_fmt\": \"\u00a54476\u5104\", \"investing_cf\": -227365000000.0, \"investing_cf_fmt\": \"-\u00a52274\u5104\", \"financing_cf\": -141006000000.0, \"financing_cf_fmt\": \"-\u00a51410\u5104\", \"free_cf\": 392701000000.0, \"free_cf_fmt\": \"\u00a53927\u5104\", \"net_margin\": 33.09, \"roe\": 20.37, \"roa\": 17.54}, {\"year\": 2023, \"revenue\": 1111367000000.0, \"revenue_fmt\": \"\u00a51.1T\", \"gross_profit\": 698061000000.0, \"gross_profit_fmt\": \"\u00a56981\u5104\", \"operating_income\": 439174000000.0, \"operating_income_fmt\": \"\u00a54392\u5104\", \"ebit\": 443848000000.0, \"ebit_fmt\": \"\u00a54438\u5104\", \"net_income\": 325472000000.0, \"net_income_fmt\": \"\u00a53255\u5104\", \"eps\": 197.8, \"operating_margin\": 39.52, \"total_assets\": 1932547000000.0, \"total_assets_fmt\": \"\u00a51.9T\", \"total_equity\": 1625580000000.0, \"total_equity_fmt\": \"\u00a51.6T\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 458674000000.0, \"total_cash_fmt\": \"\u00a54587\u5104\", \"equity_ratio\": 84.12, \"de_ratio\": 0.0, \"current_ratio\": 4.74, \"operating_cf\": 409925000000.0, \"operating_cf_fmt\": \"\u00a54099\u5104\", \"investing_cf\": -37290000000.0, \"investing_cf_fmt\": \"-\u00a5373\u5104\", \"financing_cf\": -139331000000.0, \"financing_cf_fmt\": \"-\u00a51393\u5104\", \"free_cf\": 335667000000.0, \"free_cf_fmt\": \"\u00a53357\u5104\", \"net_margin\": 29.29, \"roe\": 20.02, \"roa\": 16.84}, {\"year\": 2022, \"revenue\": 1259726000000.0, \"revenue_fmt\": \"\u00a51.3T\", \"gross_profit\": 783475000000.0, \"gross_profit_fmt\": \"\u00a57835\u5104\", \"operating_income\": 533308000000.0, \"operating_income_fmt\": \"\u00a55333\u5104\", \"ebit\": 531227000000.0, \"ebit_fmt\": \"\u00a55312\u5104\", \"net_income\": 374429000000.0, \"net_income_fmt\": \"\u00a53744\u5104\", \"eps\": 227.57, \"operating_margin\": 42.34, \"total_assets\": 1869758000000.0, \"total_assets_fmt\": \"\u00a51.9T\", \"total_equity\": 1424387000000.0, \"total_equity_fmt\": \"\u00a51.4T\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 222169000000.0, \"total_cash_fmt\": \"\u00a52222\u5104\", \"equity_ratio\": 76.18, \"de_ratio\": 0.0, \"current_ratio\": 3.15, \"operating_cf\": 243582000000.0, \"operating_cf_fmt\": \"\u00a52436\u5104\", \"investing_cf\": -145465000000.0, \"investing_cf_fmt\": \"-\u00a51455\u5104\", \"financing_cf\": -145641000000.0, \"financing_cf_fmt\": \"-\u00a51456\u5104\", \"free_cf\": 172343000000.0, \"free_cf_fmt\": \"\u00a51723\u5104\", \"net_margin\": 29.72, \"roe\": 26.29, \"roa\": 20.03}, {\"year\": 2021, \"revenue\": 0, \"revenue_fmt\": \"N\/A\", \"gross_profit\": 0, \"gross_profit_fmt\": \"N\/A\", \"operating_income\": 0, \"operating_income_fmt\": \"N\/A\", \"ebit\": 0, \"ebit_fmt\": \"N\/A\", \"net_income\": 0, \"net_income_fmt\": \"N\/A\", \"eps\": 0, \"operating_margin\": 0, \"total_assets\": 0, \"total_assets_fmt\": \"N\/A\", \"total_equity\": 0, \"total_equity_fmt\": \"N\/A\", \"total_debt\": 0, \"total_debt_fmt\": \"N\/A\", \"total_cash\": 0, \"total_cash_fmt\": \"N\/A\", \"equity_ratio\": 0, \"de_ratio\": 0, \"current_ratio\": 0, \"operating_cf\": 0, \"operating_cf_fmt\": \"N\/A\", \"investing_cf\": 0, \"investing_cf_fmt\": \"N\/A\", \"financing_cf\": 0, \"financing_cf_fmt\": \"N\/A\", \"free_cf\": 0, \"free_cf_fmt\": \"N\/A\", \"net_margin\": 0, \"roe\": 0, \"roa\": 0}], \"has_data\": true}, \"dividends\": {\"history\": [{\"year\": 2022, \"amount\": 78.0}, {\"year\": 2023, \"amount\": 80.0}, {\"year\": 2024, \"amount\": 98.0}, {\"year\": 2025, \"amount\": 272.0}, {\"year\": 2026, \"amount\": 66.0}], \"latest\": 66.0, \"has_data\": true}}","ma_5_value":0,"ma_5_deviation":0,"ma_5_trend":"","ma_25_value":0,"ma_25_deviation":0,"ma_25_trend":"","ma_75_value":0,"ma_75_deviation":0,"ma_75_trend":"","ma_200_value":0,"ma_200_deviation":0,"ma_200_trend":"","previousClose":0,"open":0,"dayHigh":0,"dayLow":0,"volume":0,"averageVolume":0,"revenueGrowth":0},"sector":[],"class_list":["post-6836","company","type-company","status-publish","hentry"],"yoast_head":"\n